Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients with Previously Treated Lyme
A New Treatment Study for Previously Treated Lyme Disease Patients with Persistent Fatigue
Sponsor: Columbia Lyme & Tick-Borne Diseases Research Center
Enrolling: Male and Female Patients
Study Length: 98 Days
Clinic Visits: 2
IRB Number: 7755
U.S. Govt. ID: NCT03891667
Contact: Lyme Center: 646-774-7503 / lymecenter@cumc.columbia.edu
Additional Study Information: Are you suffering from chronic fatigue that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new treatment research study investigates whether disulfiram, commonly known as "Antabuse", has the potential to be used as a treatment option for patients experiencing chronic post-treatment Lyme symptoms. This well-known, FDA approved drug is currently used to help individuals with alcohol dependence resist consumption; however, new scientific research has demonstrated that disulfiram is a potent killer of the Lyme bacteria in the laboratory setting. The primary goals of this study are to assess safety, side-effects, and effectiveness of disulfiram in reducing symptoms in patients with post-treatment Lyme symptoms. This study will take place over the course of 16 weeks and will enroll patients with several Telehealth visits and only 2 in-person visits to our research center in New York City. Participants will be placed on either a 4-week or 8-week, fixed flexible dosing regimen of disulfiram. Patients will be required to visit their local Quest Diagnostics laboratory center for close monitoring throughout the trial.
This study is closed
Brian Fallon, MD
Do You Qualify?
Between the ages 18-65? Yes No
Diagnosed with Lyme Disease within the past 16 years? Yes No
Willing to provide records of positive Lyme diagnosis and treatment? Yes No
Treated with Antibiotics for Lyme Disease? Yes No
Willing to visit our Center in NYC for 2 visits? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Lyme Center